| Similar Articles |
|---|
 |
The Motley Fool
September 24, 2007
Brian Lawler |
An Array of Good News Small pharmaceutical firm Array BioPharma signs a big partnership deal with Celgene. Investors, take note.   |
Chemistry World
July 29, 2015
Phillip Broadwith |
Celgene to buy immune-inflammatory specialist Receptos The deal gives Celgene access to Receptos's pipeline of inflammation and immunology treatments. |
The Motley Fool
January 11, 2011
Brian Orelli |
An Undeserved Kick in the Pants Celgene gets knocked around. |
The Motley Fool
November 4, 2011
Luke Timmerman |
Celgene to Pump $45M Into Quanticel to Discover Cancer Drugs Celgene strikes an unusual agreement. |
The Motley Fool
July 24, 2009
Brian Orelli |
Juicing Up the Earnings Report How did Celgene turn an earnings release that met analysts' expectations while lowering revenue guidance on one of its drugs into an 18.6% increase in share price yesterday? |
The Motley Fool
January 28, 2011
Brian Orelli |
Celgene Needs a Rocket Ship Celgene really needs a hit from Abraxane and other drugs it may license or purchase. |
The Motley Fool
June 30, 2010
Brian Orelli |
Celgene Jumps on a Platform Investors don't seem too enamored with Celgene's announcement that it's purchasing fellow cancer drugmaker Abraxis Bioscience although it looks like a good move in the long term. |
The Motley Fool
October 11, 2011
Arlene Weintraub |
Agios and Celgene: Anatomy of an Ultra-Valuable Biotech Marriage An unprecedented cancer drug development deal. |
The Motley Fool
January 29, 2010
Brian Orelli |
Wake Up! You Still Have to Pay Attention We already knew Celgene's preliminary numbers, but the conference call offers a look ahead. |
The Motley Fool
February 6, 2007
Brian Lawler |
Celgene Mints the Green Stuff Biotech firm Celgene reports its 2006 financial results and provides an update for its 2007 guidance. Biopharma investors know it's not the past that matters the most in this sector; it's the outlook. |
The Motley Fool
April 30, 2010
Brian Orelli |
New CEO, Same Old Double-Digit Increases Another strong quarter from Celgene. |
The Motley Fool
December 7, 2009
Brian Orelli |
When the Big Guns Come In, You Get Blasted Larger drug companies may want to gobble up smaller drug firms like Allos Therapeutics and Gloucester Pharmaceuticals. |
Scientific American
January 2009
Charles Q. Choi |
Do White Blood Cells Make Cancer Deadly? The ability to spread underlies the killing power of cancer. The process occurs, John Pawelek thinks, when tumor cells fuse with white blood cells -- an idea that, if right, could yield new therapies |
The Motley Fool
March 26, 2008
Brian Lawler |
Celgene Brings in an Orphan The Food and Drug Administration grants a Celgene drug orphan designation. Amrubicin may have an easier time in development for use in a limited patient population. |
AskMen.com
Jacob Franek |
New Cancer Therapies As cancer research explodes, the availability of new and innovative interventions is expanding almost daily. |
Chemistry World
July 8, 2015
Phillip Broadwith |
Celgene backs immunotherapy with Juno collaboration US biopharmaceutical firm Celgene is to bolster its position in the emerging field of cell therapy through a collaboration with biotech Juno Therapeutics. |
BusinessWeek
May 12, 2011
Robert Langreth |
Big Pharma Bets on a Novel Cancer Cure Research in epigenetics is booming. The payoff could be in the billions. |
The Motley Fool
April 28, 2011
Brian Orelli |
Celgene Gets No Love The market shrugs off a solid quarter. |
The Motley Fool
June 8, 2010
Rich Smith |
This Just In: Upgrades and Downgrades Is Celgene the new Genentech? Maybe not -- but it's cheap. |
The Motley Fool
November 20, 2007
Brian Orelli |
Celgene Buys a Sales Force Pharmaceutical Celgene acquires Pharmion for $2.9 billion, hoping that Pharmion's two drugs in mid-to-late clinical trials will justify the purchase price in the not-too-distant future. |
The Motley Fool
January 13, 2009
Brian Orelli |
Celgene's Still Surging With returns over the last five years that just about any investor would love to have, it might be fair to wonder whether Celgene can keep it up. It seems it can. |
The Motley Fool
October 27, 2006
Jack Uldrich |
Nanotech and the War on Cancer New imaging advances in nanotechnology will help speed cancers' end. What does it mean for investors? |
The Motley Fool
May 8, 2007
Brian Lawler |
Unstoppable Celgene The biotech powerhouse continues its strong financial results as Revlimid sales grow. |
The Motley Fool
December 9, 2009
Brian Orelli |
Rising From the ASHes At the Super Bowl of blood cancer, the American Society of Hematology's annual conference, the presentations by drug companies made a few stocks catch on fire, while a couple burned up a little. |
The Motley Fool
December 14, 2006
Brian Lawler |
Celgene Faces a Generic Challenge An abbreviated application is only an opening salvo in Barr's challenge to Celgene's Thalomid patents. Investors, take note. |
The Motley Fool
October 6, 2010
Brian Orelli |
Celgene Is All Grown Up An acquirer is on the prowl. |
The Motley Fool
April 1, 2009
Brian Orelli |
Conservative Celgene's Conundrum The drugmaker said it expected to make the low end of its previous guidance ranges for non-GAAP revenue and earnings per share for the year. It's not bad news, but it hurt the company nonetheless. |
The Motley Fool
October 30, 2006
Brian Lawler |
Celgene: Drug Kingpin Trading at 129 times trailing-12-month adjusted earnings, the biopharmaceutical looks ridiculously expensive, until one considers its awesome sales and earnings growth in that time period. Investors, take note. |
The Motley Fool
July 29, 2010
Brian Orelli |
This Best Biotech Is Cheaper Than You Think The cancer-drug specialist justifies its valuation quite effectively with a stellar second-quarter performance. |
